Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Oncotarget
October 2016
Center of Cardiovascular Diseases, First Hospital of Jilin University, Changchun, China.
Different chemotherapy drugs are generally introduced in clinical practices combining with therapy for glioma treatment. However, these chemotherapy drugs have rarely been compared with each other and the optimum drug still remains to be proved. In this research, medical databases were consulted, PubMed, Embase and Cochrane Library included.
View Article and Find Full Text PDFPhase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
J Neurooncol
October 2010
Department of Radiation Oncology, University of California, San Francisco, 1600 Divisadero, San Francisco, CA 94143, USA.
To report long-term results for children with low-grade hypothalamic/chiasmatic gliomas treated on a phase II chemotherapy protocol. Between 1984 and 1992, 33 children with hypothalamic/chiasmatic LGGs received TPDCV chemotherapy on a phase II prospective trial. Median age was 3.
View Article and Find Full Text PDFReversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.
Jpn J Cancer Res
November 2001
Research Institute of Life Science, Snow Brand Milk Products Co., Ltd., Ishibashi-machi, Shimotsuga-gun, Tochigi 329-0512.
SNF4435C and D, novel immunosuppressants produced by a strain of Streptomyces spectabilis, were examined for their reversing effects in vitro on various multidrug-resistant (MDR) tumor cells overexpressing P-glycoprotein. These two compounds in the range of 3-10 microM completely reversed the resistance of MDR variant cells, mouse leukemia P388 cells [vincristine (VCR)-resistant P388/VCR and adriamycin (ADM)-resistant P388/ADM], human myelogenous leukemia K562 cells (VCR-resistant K562/VCR and ADM-resistant K562/ADM) and human ovarian cancer A2780 cells (ADM-resistant AD(10)), against VCR. Both compounds moderately potentiated the sensitivity of the MDR cells to ADM but the reversal was not complete.
View Article and Find Full Text PDF[Pharmacokinetic study of dibromodulcitol in children with brain tumors].
Orv Hetil
November 1994
Semmelweis Orvostudományi Egyetem, II, Budapest, sz. Gyermekklinika.
Systemic pharmacokinetics of high-dose (500 mg/m2), orally administered dibromodulcitol (Elobromol) were studied in 16 chemotherapeutic courses administered to 5 patients. Cerebrospinal fluid dibromodulcitol levels were also analysed in two patients. Bromoepoxydulcitol, dianhydrodulcitol are cytotoxic, whereas bromoanhydrodulcitol, andhydroepoxydulcitol are inactive metabolites detectable during the biotransformation of dibromodulcitol.
View Article and Find Full Text PDFPharmacokinetic studies on Elobromol in children with brain tumors.
Anticancer Drugs
October 1994
Second Department of Pediatrics, Semmelweis Medical School, Budapest, Hungary.
Systemic pharmacokinetics of high dose (500 mg/m2), orally administered Elobromol (dibromodulcitol, DBD) were studied in 16 chemotherapeutic courses administered to five patients. Cerebrospinal fluid (CSF) DBD levels were also analyzed in two patients. Bromoepoxydulcitol (BED), dianhydrodulcitol (DAD) are cytotoxic, whereas bromoanhydrodulcitol (BAD) and anhydroepoxydulcitol (AED) are inactive metabolites detectable during the biotransformation of DBD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!